ImClone and Bristol-Myers Squibb
Team up for Erbitux

ImClone Systems and Bristol-Myers Squibb are working together on a lead product, Erbitux (Cetuximab), used to treat patients with colorectal disease. Erbitux is an IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR). They have submitted an application with the Japanese Pharmaceuticals and Medical Devices Agency for the use of Erbitux (Cetuximab). The filing in Japan leads into the development of collaboration between ImClone Systems, Bristol-Myers Squibb and Merck. The Japanese submission was based on results from studies conducted in Europe and Japan which confirm the activity of Erbitux in patients with metastatic colorectal cancer.

About ImClone Systems
ImClone Systems is dedicated to developing and commercializing novel therapeutic products in the field of oncology. Their efforts have resulted in a broad spectrum of innovative product candidates with potential application in multiple tumor types. ImClone Systems operates in two locations. Its corporate and scientific headquarters is in New York City, which houses the company’s research and executive offices, and its campus in Branchburg, New Jersey. The Branchburg facility is home to the manufacturing, product development, finance, clinical, regulatory and quality assurance and commercial operations departments.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb manufactures hundreds of different products and is a leader in the discovery and manufacture of innovative therapies for cardiovascular disease, central nervous system disorders, oncology, virology, metabolics, and immunology.

Contact details:
ImClone Systems
Address: 180 Varick Street,
New York 10014
Tel: +212 645 1405
Fax: +212 645 2054
Email: media@imclone.com
URL: www.imclone.com

Contact Details:
Bristol-Myers Squibb
Address: 345 Park Avenue,
New York,
USA
URL: www.bms.com